Social Value, Beneficial Information, and Obligations to Participants in a Trial of Novel COVID-19 Vaccines.

The article describes researchers who are seeking ethics guidance on communicating with participants in a phase-1 COVID-19 vaccine trial on U.S. Food and Drug administration-authorized COVID-19 vaccines. Topics include suggestion for researchers if some of the trial vaccines are viable candidates, the need to ensure equitable access to safe and effective vaccines, and argument of some bioethicists on obligations that researchers might have based on their relationships with study participants.